KoreConX Launches to Disrupt the Equity Crowdfunding Market by Offering a Free, All-in-One Solution to Help Companies Navigate Process of Raising Equity Capital
KoreConX Launches to Disrupt the Equity Crowdfunding Market by Offering a Free, All-in-One Solution to Help Companies Navigate Process of Raising Equity Capital
www.superpowers4good.com
Secure Platform Prepares Users for Due Diligence and Simplifies Shareholder Communications to Reduce Risk Toronto, Canada – November 4, 2015 – Equity crowdfunding is broken. The system does not work for many companies because of the complicated process, the enormous legal fees and the extreme importance of doing everything required to meet regulatory requirements. There has never been a simple, secure, cost-effective and legally sound solution – until now. KoreConX today introduced a powerful and free all-in-one solution that will disrupt the market by helping companies navigate the equity funding process, while simplifying shareholder communication to reduce risk.
KoreConX Launches to Disrupt the Equity Crowdfunding Market by Offering a Free, All-in-One Solution to Help Companies Navigate Process of Raising Equity Capital
KoreConX Launches to Disrupt the Equity…
KoreConX Launches to Disrupt the Equity Crowdfunding Market by Offering a Free, All-in-One Solution to Help Companies Navigate Process of Raising Equity Capital
Secure Platform Prepares Users for Due Diligence and Simplifies Shareholder Communications to Reduce Risk Toronto, Canada – November 4, 2015 – Equity crowdfunding is broken. The system does not work for many companies because of the complicated process, the enormous legal fees and the extreme importance of doing everything required to meet regulatory requirements. There has never been a simple, secure, cost-effective and legally sound solution – until now. KoreConX today introduced a powerful and free all-in-one solution that will disrupt the market by helping companies navigate the equity funding process, while simplifying shareholder communication to reduce risk.